It's a massive project. The cost and logistical issues of distribution are huge, and it's part of why being first to announce is only a part of the story.
Vaccines with simpler storage requirements (a fridge!) will be needed. A vaccine that works with a single shot (rather than two doses three weeks apart) will be a big deal. And that's before you even look at issues like suitablity across age/comorbidity groups, and price.
Manufacturing, in the short term, isn't a minor issue either. Even big companies like Pfizer are hunting for the right kind of manufacturing capacity.
Smaller companies like Novavax (which has a vaccine at Phase 3) are trying to set up manufacturing deals globally, but meanwhile they've struggled even to get contract manufacturing capacity for their expansion of Phase 3 trials.
That's also a reminder of how these vaccines are cutting the development time. Normally a small company like Novavax would have a much smaller Phase 3 study group running for much longer to get enough cases to check for efficacy. Only then would they go looking for more money (and manufacturing capacity) to increase the number of Phase 3 test subjects.
Incidentally, completing the loop, Novavax may well end up doing a deal with Pfizer. While Pfizer create/expand their mRNA capacity, their older conventional vaccine units may start producing the Novavax vaccine. All very normal stuff in the industry but with arrangements and negotiations taking place over a few weeks, rather than the many months (or even years) that it would normally take.
